FDA accelerated approval covers Padcev plus Keytruda in urothelial carcinomaNov 9Regulatory decisionenfortumab vedotinMerck & Co., Inc.
FDA approves fruquintinib for refractory metastatic colorectal cancerNov 6Regulatory decisionfruquintinib
IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipelineOct 28Quarterly updateBristol Myers SquibbEli LillyUpdated
FDA clears atezolizumab combo for Stage III dMMR colon cancerOct 8Regulatory decisionatezolizumabatezolizumab and hyaluronidase-tqjs
FDA approves Ziihera-based regimens for first-line HER2+ gastroesophageal cancerAug 25Regulatory decisionBeiGeneJazz Pharmaceuticals
Cypherpunk's Leap Therapeutics subsidiary aligns with FDA on Phase 3 trial for sirexatamabAug 12Quarterly updateCypherpunk Technologies Inc.
BeiGene's LBL-007/tislelizumab colorectal cancer trial posts resultsJun 30Trial updatealcestobartBeiGene